Next Article in Journal
ATP-Independent Initiation during Cap-Independent Translation of m6A-Modified mRNA
Next Article in Special Issue
Combined Naïve Bayesian, Chemical Fingerprints and Molecular Docking Classifiers to Model and Predict Androgen Receptor Binding Data for Environmentally- and Health-Sensitive Substances
Previous Article in Journal
Mammalian Neuropeptides as Modulators of Microbial Infections: Their Dual Role in Defense versus Virulence and Pathogenesis
Previous Article in Special Issue
Structure-Activity Relationship Modeling and Experimental Validation of the Imidazolium and Pyridinium Based Ionic Liquids as Potential Antibacterials of MDR Acinetobacter baumannii and Staphylococcus aureus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 7
10.3390/ijms22073659
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Selective COX-2 Inhibition and In Silico Study of Kuwanon Derivatives Isolated from Morus alba

by
Seung-Hwa Baek
1,2,†,
Sungbo Hwang
1,†,
Tamina Park
1,3,
Yoon-Ju Kwon
4,
Myounglae Cho
4 and
Daeui Park
1,2,3,*
1
Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon 34114, Korea
2
Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea
3
Department of Human and Environmental Toxicology, University of Science and Technology, Daejeon 34113, Korea
4
National Institute for Korean Medicine Development, Gyeongsan 38540, Korea
*
Author to whom correspondence should be addressed.
†
Equally contributed to this work.
Int. J. Mol. Sci. 2021, 22(7), 3659; https://doi.org/10.3390/ijms22073659
Submission received: 1 March 2021 / Revised: 26 March 2021 / Accepted: 26 March 2021 / Published: 1 April 2021
(This article belongs to the Special Issue Chemoinformatics and Bioinformatics Tools in Structure-Activity Modelling in Molecular Sciences)
Browse Figures
Review Reports Versions Notes

Abstract

:
Six kuwanon derivatives (A/B/C/E/H/J) extracted from the roots of Morus alba L. were evaluated to determine their cyclooxygenase (COX)-1 and 2 inhibitory effects. Cyclooxygenase (COX) is known as the target enzyme of nonsteroidal anti-inflammatory drugs (NSAIDs), which are the most widely used therapeutic agents for pain and inflammation. Among six kuwanon derivatives, kuwanon A showed selective COX-2 inhibitory activity, almost equivalent to that of celecoxib, a known COX inhibitor. Kuwanon A showed high COX-2 inhibitory activity (IC50 = 14 μM) and a selectivity index (SI) range of >7.1, comparable to celecoxib (SI > 6.3). To understand the mechanisms underlying this effect, we performed docking simulations, fragment molecular orbital (FMO) calculations, and pair interaction energy decomposition analysis (PIEDA) at the quantum-mechanical level. As a result, kuwanon A had the strongest interaction with Arg120 and Tyr355 at the gate of the COX active site (−7.044 kcal/mol) and with Val89 in the membrane-binding domain (−6.599 kcal/mol). In addition, kuwanon A closely bound to Val89, His90, and Ser119, which are residues at the entrance and exit routes of the COX active site (4.329 Å). FMO calculations and PIEDA well supported the COX-2 selective inhibitory action of kuwanon A. It showed that the simulation and modeling results and experimental evidence were consistent.

1. Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic agents to manage pain and inflammation. NSAIDs exert their pharmacological action by inhibiting cyclooxygenase (COX) enzymes, which catalyze the conversion of arachidonic acid to prostaglandins, prostacyclins, and thromboxanes [1]. COX-1, an enzyme in a constitutive form, is expressed in several tissues and is known to play an important role in the synthesis of cytoprotective prostaglandins in the gastrointestinal tract. COX-2, a predominantly induced form of the enzyme, is also constitutively expressed in many tissues such as the prostate, endothelium, brain, and renal medulla [2,3]. COX-3, a protein derived from COX-1, is mainly found in the heart and cerebral cortex [4]. COX-1 is a housekeeping enzyme that is widely expressed in most tissues, whereas COX-2, mainly expressed at sites of infection, inflammation, and cancer, produces prostanoids which are responsible for disease pathogenesis. The two COX isoforms, COX-1 and COX-2, are NSAID targets [5]. The therapeutic anti-inflammatory action of NSAIDs is associated with the inhibition of COX-2; however, undesired side effects arise from the inhibition of COX-1 [6]. Therefore, there is a need for research on anti-inflammatory substances having an improved COX-1/2 selectivity index.
Morus alba L. belongs to a genus of flowering plants of the family Moraceae. It is widespread in Japan, India, China, and Korea, as well as in Europe, North and South America [7]. Morus alba L. contains many biologically active compounds such as steroids [8], terpenoids [9], alkaloids [10], stilbenes [11], coumarins [12], and flavones such as kuwanon derivatives [13,14,15]. Because of their high flavonoid content, the leaves, fruits, and bark of Morus alba L. have long been used to prepare medicines, especially for the treatment of cutaneous inflammation [16], psychotics [17], sputum [18], and asthma [19]. Although the recent study reported the inhibitory activity of constituents of Morus alba L. as COX inhibitors, the COX-1/2 selectivity index on kuwanon derivatives has not yet been studied [20].
COX-2 protein consists of an N-terminal epidermal growth factor-like domain, a membrane-binding domain, a peroxidase active site, and a COX active site [21]. The membrane-binding domain contains four α-helices that form a hydrophobic surface, which bind to a single leaflet of the lipid bilayer on the luminal side of the endoplasmic reticulum and the nuclear envelope [22]. The membrane-binding domain also forms the entrance of a narrow hydrophobic channel, which is the COX active site [23]. The membrane-binding domain and the COX active site are separated by three conserved residues, Arg120, Tyr355, and Glu524, which act as the gate of the COX active site [21,22,23,24]. This active site forms a small and narrow pocket that extends approximately 25 Å into a globular catalytic domain that is about 8 Å wide on average [23], and to which only small molecules like celecoxib can bind.
In the present study, six kuwanon derivatives were isolated from Morus alba L., and their selective inhibitory activities against COX-1/2 were investigated. To study the molecular interaction between COX-2 and kuwanon derivatives, ab initio quantum mechanical (QM) calculations were performed, including the fragment molecular orbital (FMO) method [25] and pair interaction energy decomposition analysis (PIEDA) [26], which provide accurate molecular interaction information based on wave function. For the FMO method, we applied the density-functional tight-binding (DFTB) method which is an efficient semi-empirical QM method expected to provide reasonable accuracy [27].

2. Results

2.1. Isolation and Identification of Compounds

Six natural products were isolated from Mori cortex (roots of Morus alba L.) and identified by comparing HPLC peak profiles (Figure S1) and NMR data (Figures S2 and S3) with literature values: kuwanon A [28,29], kuwanon B [28,29], kuwanon C [28,29,30], kuwanon E [31], kuwanon G [32], and kuwanon H [32]. The structures of the six compounds are shown in Figure 1.

2.2. Analysis of COX-1/2 Enzyme Inhibitory Activity

To evaluate the activity of the kuwanon derivatives compared to that of celecoxib, the inhibitory activity of the isolated compounds against ovine COX-1 and COX-2 was evaluated (Table 1). Kuwanon A and G did not inhibit COX-1 action up to 100 μM. Kuwanon A showed a reasonable COX-2 inhibitory activity in vitro, with an IC50 of 14 μM and a selectivity index of >7.1; it was the most potent inhibitor among the kuwanon derivatives, with effects nearly similar to those of celecoxib.

2.3. Docking Simulation

To determine the binding pose of the kuwanon derivatives on COX-2, we performed docking simulation except for kuwanon G, because it had no COX-2 inhibition activity. Since the molecular weight and volume for the kuwanon derivatives were higher than those of celecoxib (Table 2), the binding site of the kuwanon derivatives was used as the binding pocket of the podophyllotoxin structure in chemocoxib A. The pocket of podophyllotoxin represents the gate of the COX active site consisting of Arg120 and Tyr355. The top 20 docking scores for the kuwanon derivatives and the root mean squared distance (RMSD) from the best binding pose are listed in Table S1. All binding poses for kuwanon derivatives are described in Figure S6. To determine various conformation for binding poses, we superimposed to all binding poses for each kuwanon derivative and calculated average RMSD between the best binding poses and other poses (Figure S7). The best binding poses of kuwanon derivatives were located close to the gate of the COX active site; the configurations which were located more than 10 Å from each best binding pose were removed.

2.4. Interaction Energy in the Gate of COX Active Site

To analyze the molecular interactions between COX-2 and the kuwanon derivatives, we performed FMO calculations and PIEDA based on their docking complexes. The total interaction energy between COX-2 and top 20 binding poses for kuwanon derivatives are listed in Table S2. The binding poses for the kuwanon derivatives are described in Figure 2. All kuwanon derivatives were bound to close to the gate of the COX active site consisting of Arg120 and Tyr355. In addition, the interaction energy between kuwanon derivatives and Arg120, and Tyr355 were also calculated by FMO and PIEDA (Figure 3). Interestingly, the pair interaction energies between two amino acids and kuwanon derivatives were closely related to their COX-2 inhibition activity. The Pearson-correlation coefficient between IC50 and the summation of pair interaction energies was calculated to be 0.920. As a result, the COX inhibition activity of kuwanon derivatives was related to their interactions with Arg120 and Tyr355.

2.5. Interaction Energy in the Membrane-Binding Domain and the Entrance/Exit Routes of COX Active Sites

To understand the differences in COX-2 inhibition activity among kuwanon derivatives, we calculated the pair interaction energies between amino acids consisting of the membrane-binding domain and kuwanon derivatives using FMO and PIEDA. The positive control compound used the podophyllotoxin of chemocoxib A bound to the membrane-binding domain of COX-2 (PDB ID: 4OTJ). Among amino acids consisting of the membrane-binding domain, five amino acids were selected as the lowest pair interaction energies (Table 3). The amino acids were Lys79, Lys83, Val89, Leu117, and Tyr122. In the binding site, the His122 in human COX-2 was Tyr122 in murine COX-2. (Figure S5). The structure of chemocoxib A bound to COX-2 is described in Figure 4.
Next, we compared the pair interaction energy between residues in the entrance and exit routes of the COX active site and kuwanon derivatives. In the previous study [21], Val89, His90, and Ser119 played a major role as the entrance/exit routes of the COX active site. Interestingly, the pair interaction energies between Val89 and kuwanon A (−6.599 kcal/mol) and H (−6.257 kcal/mol) were higher than the other derivatives (Table 3).
We also calculated the average closest distance from Val89, His90, and Ser119, located on the entrance/exit route, to the kuwanon derivatives, to determine how well these derivatives blocked this route. The closest distances between these residues and the kuwanon derivatives are listed in Table 4.
The average closest distance from these residues is as follows: 4.329 Å for kuwanon A, 4.812 Å for kuwanon B, 4.303 Å for kuwanon C, 4.430 Å for kuwanon E, and 3.592 Å for kuwanon H, the closest to these residues. Although kuwanon C is located closer to Val89 residue than kuwanon A, the pair interaction energy score with Val89 was a positive energy score (EX score: 8.521 kcal/mol, Table 3) for kuwanon C. This means that kuwanon C could have steric repulsion interaction with Val89. The pair interaction energy of Val89 supports that kuwanon A and kuwanon H have higher COX-2 inhibition activity than other derivatives.

3. Discussion

Six kuwanon compounds isolated from the roots of M. alba L. were tested with an in vitro COX-1/2 inhibition assay. Kuwanon A and H demonstrated better COX-2 inhibitory activity than celecoxib. Kuwanon A exhibited better inhibitory activity against COX-2 compared to COX-1, with an excellent COX-2 selectivity index of >7.1. These results showed that kuwanon A was a potent inhibitor of COX-2 enzymes, even better than celecoxib. In addition, kuwanon H was observed to inhibit COX-1 although kuwanon H has higher COX-2 inhibition activity than other derivatives. As gastrointestinal disease, bleeding, and increased cardiovascular risk are known side effects of COX-1 inhibition [33], the development of COX-2 selective inhibitors is important.
The molecular weights and volumes of the kuwanon derivatives are larger than celecoxib but smaller than chemocoxib A. Since the size of the COX active site is similar to that of celecoxib, kuwanon derivatives could not bind to the COX active site like celecoxib. The residues Arg120 and Tyr355 at the gate of the COX active site are important residues for binding by NSAIDs. When there is no ligand in the COX active site, the gate of the COX active site is in its closed form; however, the gate of the COX active site converts to the open form when arachidonic acid, the COX substrate, approaches the binding site. In a previous study, the conformation change for the gate of the COX active site was determined using molecular dynamics simulation [34]. This conformational change increases the size of the gate of the COX active site and becomes a structure capable of ligand binding. This conformational change could also be confirmed by superimposing murine and human COX (Figure S4). In addition, Arg120, Tyr355, and Glu524 interact with the ligand through hydrogen bonding, stabilizing it in the active site [23,24,34]. For these reasons, the interaction between Arg120/Tyr355 and the kuwanon derivatives plays an important role in determining their COX-2 inhibitory activity. As a result, both kuwanon A and H showed strong interactions with Arg120 and Tyr355 in the gate of the COX active site (interaction energies of −7.044 kcal/mol and −8.863 kcal/mol, respectively). The Pearson correlation coefficient between IC50 and the summation of pair interaction energies was calculated to be 0.920.
A previous study suggested that Val89, His90, and Ser119 play a major role as the entrance and exit route of the COX active site [21]. Also, Val89 is a member of the membrane binding domain of COX protein. All kuwanon derivatives interacted strongly with Lys83 and Val89, with an absolute pair interaction energy greater than 4 kcal/mol (Table 3). Interestingly, the pair interaction energies between Val89 and kuwanon A (−6.599 kcal/mol) and H (−6.257 kcal/mol) were higher than other derivatives. In addition, the interaction between kuwanon derivatives and Lys83 was primarily through electrostatic and hydrophobic interactions. Electrostatic interactions with Lys83 are formed through the oxygen atom in the alcohol or ketone group of the kuwanon derivatives. Although kuwanon C showed high energy scores in electrostatic and hydrophobic interactions, it was also calculated to have a strong steric repulsion with Val89 since the distance between a hydrogen atom in a benzene-1,3-diol group and Val89 was calculated to be small. Therefore, kuwanon A and kuwanon H are more stably bound to COX-2 than other derivatives and these derivatives also have high COX-2 inhibition activity.

4. Materials and Methods

4.1. Materials

The roots of Morus alba L. were purchased from a commercial herbal market on May 2014 at Yeongcheon, Gyeongbuk, Korea. The organic solvents such as methanol (MeOH), chloroform (CHCl3), ethyl acetate (EtOAc), acetone, and n-hexane (Hx) were purchased from Duksan Chemical Co. (Seoul, Korea). Silica gel 60 (Merck 70–230 mesh, 230–400 mesh, ASTM, Germany) and octadecyl silica gel (ODS-A, 12 nm, S-150 m, YMC, Tokyo, Japan) were used for column chromatography. The NMR spectra were recorded on a JEOL ECX-500 spectrometer, operating at 500 MHz for 1 h and 125 MHz for the 13C NMR spectrum (JEOL Ltd., Tokyo, Japan). The high performance liquid chromatography (HPLC) system was an Agilent 1260 series (Agilent Inc., Santa Clara, CA, USA) equipped with a quaternary pump, a degasser, an injector, a column thermostat, a diode array detector (DAD), and an evaporative light scattering detector (ELSD).

4.2. Extraction and Isolation

The roots of M. alba L. (6 kg) were extracted three times with MeOH for 24 h at room temperature (3 × 10 L) to obtain a crude MeOH extract. The crude MeOH extract (299 g) was suspended in 2 L distilled water, and solvent partitioning was done with the same volume of Hx, EtOAc, and H2O. The EtOAc soluble fraction (110 g) was subjected to silica gel (Kieselgel 60, 70–230 mesh, Merck, Germany) column chromatography with a gradient of CHCl3/MeOH (20:1 to 0:1) to produce seven fractions (MAE 1–7). The MAE 4 fraction was separated into 13 fractions (MAE 4–1 to 4–13) by silica gel column chromatography with CHCl3/acetone (50:1 to 1:1). The subfractions MAE 4–4 and 4–5 were further purified on reversed phase (ODS-A) column chromatography with MeOH/H2O (1:9 to 9:1) to obtain kuwanon A (1) (102 mg, purity: 95.2%), kuwanon B (2) (164 mg, purity: 99.9%), kuwanon C (3) (26 mg, purity: 99.9%), and kuwanon E (4) (62 mg, purity: 99.9%). The fraction MAE 5 was isolated by silica gel column chromatography with CHCl3/acetone (30:1 to 1:1) to produce 8 subfractions (MAE 5–1 to 5–8). The subfractions MAE 5–3 and 5–4 were again subjected to chromatography using a silica gel column with CHCl3/MeOH (50:1 to 1:1), and then further purified on a reversed phase (ODS-A) column chromatography using MeOH/H2O (1:9 to 9:1) to obtain kuwanon G (5) (900 mg, purity: 98.0%), and kuwanon H (6) (193 mg, purity: 98.9%) (Figure 1). The structures of the six compounds obtained were determined by comparing their spectroscopic data with those in the literature (1–6). The determination of HPLC chromatograms was performed on an Agilent 1260 series system (Agilent Inc., Santa Clara, CA, USA) equipped with a binary pump, an autosampler, a column oven, a phenomenex kinetex C18 column (2.6 μm, 150 × 4.6 mm, Phenomenex), a photodiode array detector, and an evaporative light scattering detector (ELSD). The solvent used was 0.1% (v/v) trifluoroacetic acid (TFA) in water (solvent A) and 0.1% (v/v) TFA in acetonitrile (solvent B). The gradient elution conditions used were from 95% A/5% B at 3 min to 0% A/100% B at 30 min. The flow rate was 0.5 mL/min, and the injection volume was 3 μL.

4.3. Assay Materials

Dimethyl sulfoxide (DMSO) and COX-1/2 Inhibitor Screening Kit (BioVison, California, CA, USA) were used according to the manufacturer’s instructions. All other reagents used were of the highest purity commercially available. All samples were dissolved in DMSO at a concentration of 100 mM. The chemical structures were drawn using ChemOffice software (http://www.cambridgesoft.com (accessed on 15 August 2020)).

4.4. In Vitro COX-1/COX-2 Inhibition Assay

The ability of the test compounds to inhibit COX-1 and COX-2 isoenzymes in vitro was determined using a Biovision fluorometric COX-1/-2 inhibitor screening assay kit. Briefly, the COX assay buffer (75 μL), COX cofactor working solution (2 μL), COX probe solution (1 μL), recombinant COX-1 or COX-2 (1 μL), arachidonic acid/NaOH solution (10 μL), and test solution (10 μL) were mixed in a 96-well plate, and the fluorescence kinetics were measured for 10 min at 25 °C. The fluorescence of each well was measured with an excitation wavelength of 535 nm and an emission wavelength of 587 nm. SC560 and celecoxib were used as positive controls for the COX-1 and the COX-2 assays, respectively. Fluorescence was measured using a microplate spectrophotometer (Bio-Tek, Winooski, VT, USA). Two points (T1 and T2) in the linear range of the plot were used to obtain the corresponding fluorescence values (RFU1 and RFU2). Then, the slope for all samples (S) was calculated by dividing the net ΔRFU (RFU2 − RFU1) values by the time ΔT (T2 − T1) using the following equation:
Relative inhibition (%) = ((slope of the enzyme control − slope of S)/(slope of the enzyme control)) × 100.
The concentration of the test compound causing 50% inhibition (IC50, μM) was calculated from the concentration inhibition response curve. The selectivity indices (SI, COX-1 IC50/COX-2 IC50) were also calculated and compared with that of the standard COX-2 selective inhibitor, celecoxib. The samples were evaluated in triplicates at five different concentrations.

4.5. Docking Simulation

The target protein, human COX-2 (PDB ID: 5IKR), was obtained from the Protein Data Bank (PDB) database (https://www.rcsb.org/ (accessed on 15 September 2020)). The 3D structures of the kuwanon derivatives, kuwanon A (PubChem CID: 44258296), kuwanon B (PubChem CID: 44258295), kuwanon C (PubChem CID: 5481958), kuwanon E (PubChem CID: 10342292), kuwanon G (PubChem CID: 5281667), and kuwanon H (PubChem CID: 5281668), were prepared for docking simulation. Since kuwanon G and kuwanon H only had 2D structures, we used the ChemOffice program to convert them into 3D structures with the minimum energy. The conformational evaluation of the 3D structure generated with the energy minimization method using ChemOffice is described in the Supplementary Data. The pocket of COX-2, known as the COX active site, was not the binding site of celecoxib, but the binding site of chemocoxib A [24], because the molecular weight and volume for the kuwanon derivatives were bigger than those for celecoxib. The definition of the binding site was described in the Supplementary Data in detail. Chemocoxib A is a podophyllotoxin-indomethacin conjugate. Indomethacin, which is smaller than podophyllotoxin, is located in the COX active site. However, podophyllotoxin is bound to the membrane-binding domain. Therefore, the binding pocket of the kuwanon derivatives was defined using the superimposed binding sites from the podophyllotoxin-bound crystal structures of mouse COX-2 (PDB ID: 4OTJ). To consider conformational variability, we performed molecular docking simulation using AutoDock Vina [35]. AutoDock Vina has been applied to ligand-flexible docking. We have confirmed that AutoDock Vina provides sufficient conformational variability, which is described in the Supplementary Data. The binding poses were displayed in Chimera [36]. The molecular weights and volumes of celecoxib, chemocoxib A (podophyllotoxin-indomethacin conjugate), and kuwanon derivatives were calculated using RDKit [37].

4.6. FMO Calculation and PIEDA

The two-body FMO method was applied to all calculations in this work for the FMO2/DFTB method. All input files were prepared in compliance with the hybrid orbital projection scheme fragmentation. The two cysteine residues forming the disulfide bond were defined as one fragment. The other parameters calculated in the FMO calculation were default values while the total charges for the kuwanon conformers were defined as zero. The FMO calculation and PIEDA were performed with the 30 June 2020 R1 GAMESS version (https://www.msg.chem.iastate.edu/gamess/download.html (accessed on 15 August 2020)) [38].
PIEDA was performed based on the second-order Møller–Plesset perturbation theory and polarizable continuum model level with the 3–21G basis set. PIEDA can explain the molecular interaction between two fragments using the decomposition method. These molecular interactions include electrostatic (ES), exchange repulsion (EX), charge transfer (CT), dispersion (DI), and solvation (SL). ES and EX are represented by salt bridges, hydrogen bonds, and polar interactions; DI is represented as hydrophobic interactions, and EX is represented as steric repulsion. The pair interaction energy was calculated to find significant COX-2 residues interacting with the kuwanon derivatives as well as podophyllotoxin, which was bound in the membrane-binding domain. The significant residues were found with the Pearson-correlation coefficient between experimental inhibitory activity (IC50) and pair interaction energy.

5. Conclusions

Among the six kuwanon compounds isolated from the roots of Morus alba L., kuwanon A showed the highest COX-2 selective inhibitory activity, even higher than celecoxib. Kuwanon derivatives cannot bind to the COX active site because kuwanon derivatives are larger than celecoxib. However, kuwanon derivatives could inhibit by effectively blocking the gate of the COX active site including Arg120 and Tyr355.
Interestingly, kuwanon A had the strongest interaction with Arg120 and Tyr355 at the gate of the COX active site (−7.044 kcal/mol) and with Val89 in the membrane-binding domain (−6.599 kcal/mol). In addition, kuwanon A closely bound to Val89, His90, and Ser119, which are residues at the entrance and exit routes of the COX active site (4.329 Å). As both kuwanon A and kuwanon H interact strongly with Val89, they have higher COX-2 inhibitory activity than the other derivatives.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms22073659/s1.

Author Contributions

D.P., S.-H.B. and S.H. designed the study. S.-H.B. performed the enzyme assay experiments and D.P., S.-H.B. and S.H. analyzed the data. Y.-J.K. and M.C. were involved in the isolation and spectral analysis, and wrote part of the manuscript. D.P. and S.H. conducted the docking simulation. S.H. executed the FMO calculation and PIEDA. S.-H.B., S.H., T.P., Y.-J.K., M.C. and D.P. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

The research was supported by grants from the Korea Institute of Toxicology, Republic of Korea (KK-2111), the National Research Foundation of Korea (NRF), funded by the Korean government (2018R1D1A1B07046744), and the National Research Council of Science & Technology grant by the Korean government (CRC-16-01-KRICT).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Acknowledgments

In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Alam, M.J.; Alam, O.; Khan, S.A.; Naim, M.J.; Islamuddin, M.; Deora, G.S. Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues. Drug Des. Devel. Ther. 2016, 10, 3529–3543. [Google Scholar] [CrossRef]
  2. Zidar, N.; Odar, K.; Glavac, D.; Jerse, M.; Zupanc, T.; Stajer, D. Cyclooxygenase in normal human tissues—Is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J. Cell. Mol. Med. 2009, 13, 3753–3763. [Google Scholar] [CrossRef] [Green Version]
  3. Choi, S.-H.; Aid, S.; Bosetti, F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: Implications for translational research. Trends Pharmacol. Sci. 2009, 30, 174–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Willoughby, D.A.; Moore, A.R.; Colville-Nash, P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000, 355, 646–648. [Google Scholar] [CrossRef]
  5. Pairet, M.; Van Ryn, J.; Mauz, A.; Schierok, H.; Diederen, W.; Türck, D.; Engelhardt, G. Differential inhibition of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems. In Selective COX-2 Inhibitors; Springer: Berlin/Heidelberg, Germany, 1998; pp. 27–46. [Google Scholar]
  6. Cryer, B.; Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998, 104, 413–421. [Google Scholar] [CrossRef]
  7. Bagachi, A.; Semwal, A.; Bharadwaj, A. Traditional uses, phytochemistry and pharmacology of Morus alba Linn.: A review. J. Med. Plants Res. 2013, 7, 461–469. [Google Scholar]
  8. Ahmad, A.; Gupta, G.; Afzal, M.; Kazmi, I.; Anwar, F. Antiulcer and antioxidant activities of a new steroid from Morus alba. Life Sci. 2013, 92, 202–210. [Google Scholar] [CrossRef]
  9. Ali, A.; Ali, M. New triterpenoids from Morus alba L. stem bark. Nat. Prod. Res. 2013, 27, 524–531. [Google Scholar] [CrossRef]
  10. Asano, N.; Yamashita, T.; Yasuda, K.; Ikeda, K.; Kizu, H.; Kameda, Y.; Kato, A.; Nash, R.J.; Lee, H.S.; Ryu, K.S. Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J. Agric. Food Chem. 2001, 49, 4208–4213. [Google Scholar] [CrossRef]
  11. Qiu, F.; Komatsu, K.; Kawasaki, K.; Saito, K.; Yao, X.; Kano, Y. A novel stilbene glucoside, oxyresveratrol 3′-O-β-glucopyranoside, from the root bark of Morus alba. Planta Med. 1996, 62, 559–561. [Google Scholar] [CrossRef]
  12. Oh, H.; Ko, E.-K.; Jun, J.-Y.; Oh, M.-H.; Park, S.-U.; Kang, K.-H.; Lee, H.-S.; Kim, Y.-C. Hepatoprotective and free radical scavenging activities of prenylflavonoids, coumarin, and stilbene from Morus alba. Planta Med. 2002, 68, 932–934. [Google Scholar] [CrossRef]
  13. Nomura, T.; Fukal, T.; Katayanagi, M. Studies on the constituents of the cultivated mulberry tree. III. Isolation of four new flavones, kuwanon A, B, C and oxydihydromorusin from the root bark of Morus alba L. Chem. Pharm. Bull. 1978, 26, 1453–1458. [Google Scholar] [CrossRef] [Green Version]
  14. Nomura, T. Hypotensive constituent, kuwanon H, a new flavone derivative from the root bark of the cultivated mulberry tree (Morus alba L.). Heterocycles 1980, 14, 1943–4951. [Google Scholar] [CrossRef]
  15. Nomura, T.; Fukai, T. Kuwanon G, a new flavone derivative from the root barks of the cultivated mulberry tree (Morus alba L.). Chem. Pharm. Bull. 1980, 28, 2548–2552. [Google Scholar] [CrossRef] [Green Version]
  16. Woo, H.; Lee, J.; Park, D.; Jung, E. Protective effect of mulberry (Morus alba L.) extract against benzo [a] pyrene induced skin damage through inhibition of aryl hydrocarbon receptor signaling. J. Agric. Food Chem. 2017, 65, 10925–10932. [Google Scholar] [CrossRef] [PubMed]
  17. Rayam, S.; Kudagi, B.L.; Buchineni, M.; Pathapati, R.M.; Immidisetty, M.R. Assessment of Morus alba (mulberry) leaves extract for anti-psychotic effect in rats. Int. J. Basic Clin. Pharmacol. 2019, 8, 2130–2133. [Google Scholar] [CrossRef]
  18. Wei, H.; Zhu, J.-J.; Liu, X.-Q.; Feng, W.-H.; Wang, Z.-M.; Yan, L.-H. Review of bioactive compounds from root barks of Morus plants (Sang-Bai-Pi) and their pharmacological effects. Cogent Chem. 2016, 2, 1212320. [Google Scholar] [CrossRef]
  19. Kim, J.-M.; Baek, J.-M.; Kim, H.-S.; Choe, M. Antioxidative and anti-asthma effect of Morus bark water extracts. J. Korean Soc. Food Sci. Nutr. 2010, 39, 1263–1269. [Google Scholar] [CrossRef]
  20. Čulenová, M.; Sychrová, A.; Hassan, S.T.S.; Berchová-Bímová, K.; Svobodová, P.; Helclová, A.; Michnová, H.; Hošek, J.; Vasilev, H.; Suchý, P. Multiple In vitro biological effects of phenolic compounds from Morus alba root bark. J. Ethnopharmacol. 2020, 248, 112296. [Google Scholar] [CrossRef] [PubMed]
  21. Blobaum, A.L.; Xu, S.; Rowlinson, S.W.; Duggan, K.C.; Banerjee, S.; Kudalkar, S.N.; Birmingham, W.R.; Ghebreselasie, K.; Marnett, L.J. Action at a Distance: Action at a Distance: Mutations of Peripheral Residues Transform Rapid Reversible Inhibitors to Slow, Tight Binders of Cyclooxygenase-2. J. Biol. Chem. 2015, 290, 12793–12803. [Google Scholar] [CrossRef] [Green Version]
  22. Knights, K.M.; Mangoni, A.A.; Miners, J.O. Defining the COX inhibitor selectivity of NSAIDs: Implications for understanding toxicity. Expert Rev. Clin. Pharmacol. 2010, 3, 769–776. [Google Scholar] [CrossRef] [PubMed]
  23. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. Pharmacol. Rev. 2004, 56, 387–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Uddin, M.J.; Crews, B.C.; Xu, S.; Ghebreselasie, K.; Daniel, C.K.; Kingsley, P.J.; Banerjee, S.; Marnett, L.J. Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. ACS Chem. Biol. 2016, 11, 3052–3060. [Google Scholar] [CrossRef] [PubMed]
  25. Kitaura, K.; Ikeo, E.; Asada, T.; Nakano, T.; Uebayasi, M. Fragment molecular orbital method: An approximate computational method for large molecules. Chem. Phys. Lett. 1999, 313, 701–706. [Google Scholar] [CrossRef]
  26. Fedorov, D.G.; Kitaura, K. Pair interaction energy decomposition analysis. J. Comput. Chem. 2007, 28, 222–237. [Google Scholar] [CrossRef] [PubMed]
  27. Gaus, M.; Cui, Q.; Elstner, M. DFTB3: Extension of the Self-Consistent-Charge Density-Functional Tight-Binding Method (SCC-DFTB). J. Chem. Theory Comput. 2011, 7, 931–948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Ryu, T.-B.; Ha, T.-J.; Curtis-Long, M.-J.; Ryu, H.-W.; Gap, S.-W.; Park, K.-H. Inhibitory effects on mushroom tyrosinase by flavones from the stem barks of Morus lhou (S.) Koidz. J. Enz. Inhibi. Medici. Chem. 2008, 23, 922–930. [Google Scholar] [CrossRef] [Green Version]
  29. Nomura, T.; Fukai, T.; Katayanagi, M. Kuwanon A, B, C and oxydihydromorusin, four new flavones from the root bark of the cultivated mulberry tree (Morus alba L.). Chem. Pharm. Bull. 1977, 25, 529–532. [Google Scholar] [CrossRef] [Green Version]
  30. Tang, F.; Wang, Y.; Hou, A.-J. Total syntheses of Nigrasin I and Kuwanon C. Tetrahedron 2014, 70, 3963–3970. [Google Scholar] [CrossRef]
  31. Nomura, T.; Fukai, T.; Hano, Y.; Nemoto, K.; Terada, S.; Kuramochi, T. Constituents of cultivated mulberry tree. Planta Med. 1983, 47, 151–156. [Google Scholar] [CrossRef]
  32. Nomura, T.; Fukai, T.; Narita, T.; Terada, S.; Uzawa, J.; Iitaka, Y.; Takasugi, M.; Ishikawa, S.; Nagao, S.; Masamune, T. Confirmation of the structures of kuwanons G and H (albanins F and G) by partial synthesis. Tetrahedron Lett. 1981, 22, 2195–2198. [Google Scholar] [CrossRef]
  33. Al-Saeed, A. Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs. Oman Med. J. 2011, 26, 385–391. [Google Scholar] [CrossRef] [PubMed]
  34. Furse, K.E.; Pratt, D.A.; Porter, N.A.; Lybrand, T.P. Molecular Dynamics Simulations of Arachidonic Acid Complexes with COX-1 and COX-2:  Insights into Equilibrium Behavior. Biochemistry 2006, 45, 3189–3205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [Google Scholar] [CrossRef] [Green Version]
  36. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [Green Version]
  37. Landrum, G. RDKit: Open-Source Cheminformatics 2006. Available online: https://www.bibsonomy.org/bibtex/28d01fceeccd6bf2486e47d7c4207b108/salotz (accessed on 15 August 2020).
  38. Barca, G.M.J.; Bertoni, C.; Carrington, L.; Datta, D.; De Silva, N.; Deustua, J.E.; Fedorov, D.G.; Gour, J.R.; Gunina, A.O.; Guidez, E.; et al. Recent developments in the general atomic and molecular electronic structure system. J. Chem. Phys. 2020, 152, 154102. [Google Scholar] [CrossRef] [Green Version]
Ijms 22 03659 g001 550
Figure 1. Chemical structures of the kuwanon derivatives isolated from the roots of Morus alba L.
Figure 1. Chemical structures of the kuwanon derivatives isolated from the roots of Morus alba L.
Ijms 22 03659 g001
Ijms 22 03659 g002 550
Figure 2. Binding poses with the lowest total interaction energy for (a) kuwanon A, (b) kuwanon B, (c) kuwanon C, (d) kuwanon E, and (e) kuwanon H. All kuwanon derivatives can block the entrance of the celecoxib active site. The orange-colored surface represents the residues at the gate of the cyclooxygenase (COX) activity as calculated with the five lowest pair interaction energies, using pair interaction energy decomposition analysis (PIEDA).
Figure 2. Binding poses with the lowest total interaction energy for (a) kuwanon A, (b) kuwanon B, (c) kuwanon C, (d) kuwanon E, and (e) kuwanon H. All kuwanon derivatives can block the entrance of the celecoxib active site. The orange-colored surface represents the residues at the gate of the cyclooxygenase (COX) activity as calculated with the five lowest pair interaction energies, using pair interaction energy decomposition analysis (PIEDA).
Ijms 22 03659 g002
Ijms 22 03659 g003 550
Figure 3. The pair interaction energies between the kuwanon derivatives and the two amino acids in the gate of the COX active site. Both Arg120 and Tyr355 play a major role at the gate of the COX active site.
Figure 3. The pair interaction energies between the kuwanon derivatives and the two amino acids in the gate of the COX active site. Both Arg120 and Tyr355 play a major role at the gate of the COX active site.
Ijms 22 03659 g003
Ijms 22 03659 g004 550
Figure 4. Binding pose between chemocoxib A and COX-2 (PDB ID: 4OTJ). The orange-colored surface represents the residues at the gate of COX activity. Since the binding pose was hidden by COX-2 residues, the upper figure is represented by removing residues from Thr71 to Lys83, and the lower figure was represented by removing residues from Tyr115 to Ser119.
Figure 4. Binding pose between chemocoxib A and COX-2 (PDB ID: 4OTJ). The orange-colored surface represents the residues at the gate of COX activity. Since the binding pose was hidden by COX-2 residues, the upper figure is represented by removing residues from Thr71 to Lys83, and the lower figure was represented by removing residues from Tyr115 to Ser119.
Ijms 22 03659 g004
Table
Table 1. Results of the in vitro COX-1/2 enzyme inhibition assay.
Table 1. Results of the in vitro COX-1/2 enzyme inhibition assay.
CompoundsIC50 (μM) 1SI 2
COX-1COX-2
Kuwanon A>10014>7.1
Kuwanon B36281.3
Kuwanon C67421.6
Kuwanon E46341.4
Kuwanon G>100>100- 3
Kuwanon H3775.0
Celecoxib>10016>6.3
1 IC50 is the concentration required to produce 50% inhibition of the COX-1 or COX-2 enzyme assay. 2 SI (selectivity index, COX-1 IC50/COX-2 IC50). 3 Not determined.
Table
Table 2. Molecular weight and volume for COX-2-bound drug, components of chemocoxib A (indomethacin and podophyllotoxin), and kuwanon derivatives.
Table 2. Molecular weight and volume for COX-2-bound drug, components of chemocoxib A (indomethacin and podophyllotoxin), and kuwanon derivatives.
NameMolecular Weight (g/mol)Molecular Volume
Celecoxib381.076359.848
Chemcoxib A923.303891.808
Indomethacin357.077350.384
Podophyllotoxin456.142434.096
Kuwanon A420.157417.768
Kuwanon B420.157413.624
Kuwanon C422.173426.152
Kuwanon E424.189427.352
Kuwanon G692.226662.832
Kuwanon H760.288744.432
Table
Table 3. PIEDA of the five amino acids in the membrane-binding domain of COX-2.
Table 3. PIEDA of the five amino acids in the membrane-binding domain of COX-2.
Compound NameAmino AcidPair Interaction Energy
(kcal/mol)		Component of Pair Interaction Energy (kcal/mol) c
ESEXCTDISL
Chemocoxib A a Lys79−15.267−1.364−0.126−0.195−5.647−7.936
Lys83−10.241−2.3420.303−0.257−3.839−4.105
Tyr122−6.0490.5020.1040.000−6.321−0.334
Leu117−3.464−3.1010.0010.000−0.5650.201
Val89−3.2670.018−0.072−0.002−3.200−0.012
Kuwanon A bLys79−1.807−2.3440.0000.000−0.5311.068
Lys83−14.430−7.9950.782−0.152−8.6571.591
His122−0.830−0.8250.0000.000−0.2580.253
Leu117−0.934−1.1200.756−0.022−0.6090.061
Val89−6.599−0.7710.532−0.016−6.172−0.172
Kuwanon B bLys79−1.4680.8390.0000.000−0.037−2.271
Lys83−1.7214.0210.0000.000−0.503−5.239
His122−0.0960.0690.0000.000−0.051−0.114
Leu117−0.024−0.1030.0000.000−0.3700.449
Val89−4.6651.0350.217−0.011−4.866−1.040
Kuwanon C bLys79−3.1640.158−0.0030.000−1.035−2.285
Lys83−14.541−7.3303.374−0.198−7.612−2.775
His122−0.830−0.8250.0000.000−0.2580.253
Leu117−0.934−1.1200.756−0.022−0.6090.061
Val894.212−0.1548.521−0.128−3.934−0.091
Kuwanon E bLys79−2.662−5.7990.0000.000−0.3823.518
Lys83−8.604−3.0860.050−0.001−5.367−0.200
His122−1.933−1.678−0.0010.000−0.7750.521
Leu117−0.199−0.1390.0000.000−0.3510.291
Val89−5.810−0.3280.563−0.023−5.754−0.267
Kuwanon H bLys79−3.997−0.0920.0000.000−0.434−3.471
Lys83−10.573−6.3871.361−0.033−4.870−0.645
His122−0.515−0.1500.0000.000−0.088−0.277
Leu1171.6462.2000.0000.000−0.349−0.205
Val89−6.2570.1170.334−0.002−6.521−0.185
a Pair interaction energy of chemocoxib A represents the interaction energy between podophyllotoxin and linker structures and murine COX-2 (PDB ID: 4OTJ). b Pair interaction energy of kuwanon derivatives represent the interaction energy between the kuwanon derivatives and human COX-2 (5IKR). c ES: ElectroStatic interaction, EX: EXchanged repulsion, CT: Charge Transfer, DI: Dispersion, SL: SoLvation. The bold amino acid is located in entrance/exit routes of COX-2 active sites.
Table
Table 4. The closest distance between the kuwanon derivatives and amino acids in the entrance/exit routes of COX active sites.
Table 4. The closest distance between the kuwanon derivatives and amino acids in the entrance/exit routes of COX active sites.
ResiduesClosest Distance (Å)
Kuwanon AKuwanon BKuwanon CKuwanon EKuwanon H
Val892.5952.1951.4041.9612.142
His903.9515.1095.2053.6644.857
Ser1196.4407.1326.3017.6653.778
Average4.3294.8124.3034.4303.592
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Baek, S.-H.; Hwang, S.; Park, T.; Kwon, Y.-J.; Cho, M.; Park, D. Evaluation of Selective COX-2 Inhibition and In Silico Study of Kuwanon Derivatives Isolated from Morus alba. Int. J. Mol. Sci. 2021, 22, 3659. https://doi.org/10.3390/ijms22073659

AMA Style

Baek S-H, Hwang S, Park T, Kwon Y-J, Cho M, Park D. Evaluation of Selective COX-2 Inhibition and In Silico Study of Kuwanon Derivatives Isolated from Morus alba. International Journal of Molecular Sciences. 2021; 22(7):3659. https://doi.org/10.3390/ijms22073659

Chicago/Turabian Style

Baek, Seung-Hwa, Sungbo Hwang, Tamina Park, Yoon-Ju Kwon, Myounglae Cho, and Daeui Park. 2021. "Evaluation of Selective COX-2 Inhibition and In Silico Study of Kuwanon Derivatives Isolated from Morus alba" International Journal of Molecular Sciences 22, no. 7: 3659. https://doi.org/10.3390/ijms22073659

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop